Reata Pharmaceuticals, Inc. Class A Common Stock | RETA

Daily Technical Analysis of Reata Pharmaceuticals, Inc. Class A Common Stock

There wasn't too much excitement in Reata Pharmaceuticals today which only managed to move up 0.40% on the day.

The Biotechnology company isn't at an immediate support or resistance level that might be predictive. Reata Pharmaceuticals has looked pretty good over the last few months. It has definitely cuaght a bid and had a nice run. Over the last 3 months, shareholders are no doubt pleased to see a 146.67 percent return. RETA might find some support at the 35.4 level, buyers might push the price back up from here. But it's not very clear what will happen.

Analyst Ratings for Reata Pharmaceuticals By Price Target And Rating

The analysts feel pretty optimistic about Reata Pharmaceuticals and have been assigning positive ratings. The current Analysts Sentiment Score is 250.34. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. On 2023-03-01 Barclays increased their price target by 80% to $90.00. Cantor Fitzgerald boosted their price targ by 98.36% to $121.00 on 2023-03-01. On 2023-03-01 Citigroup increased their price target by 126.42% to $120.00. On 2023-03-01 Stifel Nicolaus increased their price target by 40% to $105.00. Robert W. Baird provided a price target boost of 112.5% to $85.00 from $40.00 on 2023-03-01. SVB Securities gave a boost to their price target and moved to $75.00 from $35.00 on 2023-03-01. On 2023-02-24 The Goldman Sachs Group increased their price target by 1.74% to $117.00. Guggenheim initiated a rating of Buy on 2022-10-19 and they set their price target at $75.00.LADENBURG THALM/SH SH provided a price target decease of -10.67% to $67.00 from $75.00 on 2022-05-11. On 2021-12-09 there was confirmation of the previous rating by SVB Leerink which was Outperform and dropped their 1 year price target to $35.00 which is down from $282.00.

Earnings Per Share (EPS) Estimates By Year and Quarter

Short interest for Reata Pharmaceuticals

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Social Sentiment for Reata Pharmaceuticals

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.